EN DE
Watch Memphasys Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Memphasys Ltd (MEM) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Memphasys Ltd stock A$0.00, price A$0.00, that is 1.5% below the price, quality 29 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare AU · ISIN AU000000MEM5

ML Memphasys Ltd logo Thin data Nov 10, 2026

Memphasys Ltd

MEM · AU
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Fair value A$0.0039 · Fairly valued
Mixed Growth (revenue 5y +5.3 %/yr in AUD)
Mixed vs. peers (3/7)
Quality 29/100
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Memphasys Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.1005 A$0.0030 Fair Value A$0.0039 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range A$0.0030 – A$0.1005 · fair‑value band A$0.0039 – A$0.0040 · the A$0.0040 price screens above the A$0.0039 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Memphasys in your weekly email

Every Wednesday you see whether Memphasys is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia.

Show moreShow less

The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals.

In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.

Stock analysis

Memphasys Ltd (MEM) currently trades at A$0.0040, while our estimate is A$0.0039, so the stock looks roughly fairly valued today (gap 1.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: A$0.0039 (bear) to A$0.0040 (bull), the price of A$0.0040 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Memphasys Ltd reported revenue of A$274K in FY2026 versus A$27.1K in FY2022, a compound +78.2%/yr. Reported net income was −A$4.1M in FY2026.

Key figures

Market cap A$12.3M (≈ $8.5M) Micro · P/S ratio 18.8 · Return on equity −95.9% · Return on assets (EBIT) −27.5% (5-year average) · Operating margin −201% · Revenue (TTM) A$658K · Revenue growth (YoY) +220% · Free cash flow −A$2.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 50% below its 52-week high and 33% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −2%, MEM screens richer than that median.

Fair Value

Bear A$0.0039 Fair Value A$0.0039 Bull A$0.0040
Price A$0.0040 · Downside -1.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 28
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 33
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 23
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 27
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 7/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−48.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+161.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
Start year 2021 (pandemic). Over 10 years: +15.7% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−800.8% (2021) → −1,516.8% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

Watch MEM, get fair value alerts →

Compare Memphasys Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −1.5% · Above median
Profitability
Return on assets −36.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 220.3% · Top 25%
Balance sheet
Debt / equity 0.02× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.93× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 18.77× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)31 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs MEM
DexCom, Inc DXCM $79.92 $89.18 +12% vs MEM
Stryker Corporation SYK $324.29 $358.30 +10% vs MEM
STERIS plc STE $257.12 $279.53 +9% vs MEM
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs MEM
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs MEM
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs MEM
Abbott Laboratories, ABT $110.46 $75.28 −32% vs MEM
Medtronic plc MDT $101.59 $65.61 −35% vs MEM
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs MEM

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Memphasys Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Memphasys Ltd Fair Value". https://www.fairvalue-calculator.com/stock/MEM

Frequently asked questions

Is Memphasys Ltd (MEM) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is A$0.0039 versus a price of A$0.0040, about 2% lower (fairly valued).
What is the fair value of MEM?
Our estimate for Memphasys Ltd is A$0.0039 (as of Nov 10, 2026), built from audited fundamentals. The current price: A$0.0040.
What is the quality score of MEM?
Memphasys Ltd has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Memphasys Ltd (MEM)?
Our calculated price target is the estimate of A$0.0039 (as of Nov 10, 2026). Cautious scenario A$0.0039, optimistic scenario A$0.0040. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Memphasys Ltd stock forecast for 2026?
Our estimate puts fair value at A$0.0039, about 2% lower versus a price of A$0.0040 (fairly valued). Cautious scenario A$0.0039, optimistic scenario A$0.0040. The calculation is refreshed regularly with new filings.
What is the revenue of Memphasys Ltd (MEM)?
Memphasys Ltd reported trailing-twelve-month revenue of about A$658K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Memphasys Ltd (MEM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Memphasys Ltd it is A$0.0039 per share (as of Nov 10, 2026), against a price of A$0.0040.
Is Memphasys Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, MEM trades above its calculated fair value: price A$0.0040, fair value A$0.0039, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MEM?
No. The price is what the market pays today (A$0.0040); the fair value is what the company's own numbers justify (A$0.0039). For Memphasys Ltd the two are A$0.0001 per share apart. That gap is exactly why we show both numbers side by side.
How much is Memphasys Ltd worth?
The market values Memphasys Ltd at about A$12.3M (market capitalisation, as of Nov 10, 2026). Per share that is A$0.0040; our models calculate a fair value of A$0.0039 per share.
What do the bullish and bearish scenarios say about MEM?
Our models span a range for Memphasys Ltd: cautious scenario A$0.0039, base A$0.0039, optimistic A$0.0040 per share (as of Nov 10, 2026, price A$0.0040). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Memphasys Ltd (MEM)?
Balance-sheet figures for Memphasys Ltd (as of Nov 10, 2026): return on equity −95.9%, debt of 0.02 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is MEM from its 52-week high?
Memphasys Ltd trades at A$0.0040, about 50% below its 52-week high of A$0.0080 and 33% above the low of A$0.0030 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0039 is for.
Which stocks are comparable to Memphasys Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Memphasys Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price A$0.0040, calculated fair value A$0.0039 (−2%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Memphasys Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Memphasys Ltd (MEM)?
The closing price on Nov 11, 2026 was A$0.0040. Our estimate is A$0.0039, about 2% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Memphasys Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band (A$0.0039 to A$0.0040), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Memphasys Ltd

How large is the market capitalisation of Memphasys Ltd (MEM)?
The market capitalisation of Memphasys Ltd is A$12.3M (≈ $8.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Memphasys Ltd (MEM)?
The price-to-sales ratio of Memphasys Ltd is 18.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Memphasys Ltd (MEM)?
The return on equity (ROE) of Memphasys Ltd is −95.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Memphasys Ltd (MEM)?
On an EBIT basis the return on assets of Memphasys Ltd is −27.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Memphasys Ltd (MEM)?
The operating margin of Memphasys Ltd is −201% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Memphasys Ltd (MEM)?
Revenue at Memphasys Ltd is growing +220% versus a year earlier (3y avg +161%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Memphasys Ltd (MEM) generate?
The free cash flow of Memphasys Ltd is −A$2.5M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Memphasys Ltd (MEM) carry?
The net debt of Memphasys Ltd is A$3.1M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Memphasys Ltd in the live analysis

One click puts Memphasys Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.